Comparison of Titan Pharmaceuticals Inc. (TTNP) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

We will be contrasting the differences between Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as far as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals Inc. N/A 0.00 51.92M -1.85 0.00
Vanda Pharmaceuticals Inc. 15 0.10 40.60M 0.39 31.68

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Titan Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc.


Table 2 provides Titan Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals Inc. 30,541,176,470.59% -319.2% -106.8%
Vanda Pharmaceuticals Inc. 270,306,258.32% 8.1% 6.6%

Risk and Volatility

Titan Pharmaceuticals Inc. is 2.00% less volatile than Standard & Poor’s 500 because the company has a beta of 0.98. From a competition point of view, Vanda Pharmaceuticals Inc. has a 0.35 beta which is 65.00% less volatile compared to Standard & Poor’s 500.


The Current Ratio of Titan Pharmaceuticals Inc. is 2.1 while its Quick Ratio stands at 1.9. The Current Ratio of rival Vanda Pharmaceuticals Inc. is 5.2 and its Quick Ratio is has 5.2. Vanda Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Titan Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Titan Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Titan Pharmaceuticals Inc. 0 0 1 3.00
Vanda Pharmaceuticals Inc. 0 1 1 2.50

Titan Pharmaceuticals Inc.’s average target price is $1, while its potential upside is 431.63%. Meanwhile, Vanda Pharmaceuticals Inc.’s average target price is $18, while its potential upside is 3.03%. Based on the analysts opinion we can conclude, Titan Pharmaceuticals Inc. is looking more favorable than Vanda Pharmaceuticals Inc.

Institutional and Insider Ownership

Institutional investors held 5.1% of Titan Pharmaceuticals Inc. shares and 0% of Vanda Pharmaceuticals Inc. shares. About 4.32% of Titan Pharmaceuticals Inc.’s share are held by insiders. Insiders Competitively, held 3.6% of Vanda Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Titan Pharmaceuticals Inc. -3.48% -12.94% -32.32% -7.5% -79.44% -17.04%
Vanda Pharmaceuticals Inc. -5.61% -10.43% -22.19% -55.85% -37.59% -52.35%

For the past year Titan Pharmaceuticals Inc. has stronger performance than Vanda Pharmaceuticals Inc.


On 7 of the 13 factors Vanda Pharmaceuticals Inc. beats Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.